Trials / Recruiting
RecruitingNCT06122389
SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma
A Double-blinded, Randomized, Multi-center Phase III Clinical Study of SHR2554 Versus Chidamide in Patients With Relapsed/Refractory PTCL
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR2554; Chidamide analog tablets | SHR2554 + Chidamide analog tablets |
| DRUG | SHR2554 analog tablets; Chidamide | SHR2554 analog tablets + Chidamide |
Timeline
- Start date
- 2024-02-05
- Primary completion
- 2026-05-01
- Completion
- 2026-07-01
- First posted
- 2023-11-08
- Last updated
- 2026-01-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06122389. Inclusion in this directory is not an endorsement.